GU Cancers 2025 | Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation

Michael Schweizer • 14 Feb 2025

GU Cancers 2025

Michael Schweizer, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on findings from a Phase I study (NCT03460977) on mevrometostat, an EZH2 inhibitor, plus enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Mevrometostat showed dose-dependent EZH2 inhibition, reducing key pharmacodynamic markers and altering tumor gene expression. Tumor suppressor genes were reactivated, while genes involved in tumor progression were suppressed. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.